Deepak Gondaliya
Corporate Officer/Principal en Emcure Pharmaceuticals Ltd. .
Perfil
Deepak Gondaliya is currently working as the President-Technical Operations at Emcure Pharmaceuticals Ltd.
He previously worked as the Deputy General Manager-Research & Development at Sun Pharmaceutical Industries Ltd.
Dr. Gondaliya holds a doctorate degree from Hemchandracharya North Gujarat University.
Cargos activos de Deepak Gondaliya
| Empresas | Cargo | Inicio |
|---|---|---|
Emcure Pharmaceuticals Ltd.
 Emcure Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Emcure Pharmaceuticals Ltd. engages in developing, manufacturing and marketing of pharmaceutical products. Its products include Nucron, Xennea, Xennex, Nifirex, Criante and Oncocare. The company offers calcium channel blockers, beta blockers, hypotensive combinations, statins, anti-coagulants, and diuretic combinations for cardiology. Its product portfolio includes orals, injectable and biologics, as well as an mRNA platform through which it is developing a COVID-19 vaccine. The company was founded by Satish Ramanlal Mehta on April 16, 1981 and is headquartered in Pune, India. | Corporate Officer/Principal | 01/07/2013 |
Antiguos cargos conocidos de Deepak Gondaliya.
| Empresas | Cargo | Fin |
|---|---|---|
| SUN PHARMACEUTICAL INDUSTRIES LTD. | Corporate Officer/Principal | - |
Formación de Deepak Gondaliya.
| Hemchandracharya North Gujarat University | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| SUN PHARMACEUTICAL INDUSTRIES LTD. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Emcure Pharmaceuticals Ltd.
Emcure Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Emcure Pharmaceuticals Ltd. engages in developing, manufacturing and marketing of pharmaceutical products. Its products include Nucron, Xennea, Xennex, Nifirex, Criante and Oncocare. The company offers calcium channel blockers, beta blockers, hypotensive combinations, statins, anti-coagulants, and diuretic combinations for cardiology. Its product portfolio includes orals, injectable and biologics, as well as an mRNA platform through which it is developing a COVID-19 vaccine. The company was founded by Satish Ramanlal Mehta on April 16, 1981 and is headquartered in Pune, India. | Health Technology |
- Bolsa de valores
- Insiders
- Deepak Gondaliya
